Top Markets
Coin of the day
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Rang in aandelen #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aandeelprijs
$0.343985
Marktkapitalisatie
$15.40M
Verandering (1 dag)
3.94%
Verandering (1 jaar)
-25.19%
Land
BE
Handel Celyad Oncology S.A. (CYAD)

Categorie

Koersgeschiedenis voor Celyad Oncology S.A. (CYAD)
Hoogste slotkoers: $0.32 op 2026-08-01

Laagste slotkoers: $23.14 op 2013-07-01
Koersgeschiedenis van Celyad Oncology S.A. van 2013 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 42.82%
2025 -72.13%
2024 89.47%
2023 -54.51%
2022 -78.81%
2021 -49.40%
2020 -24.66%
2019 -46.68%
2018 -46.75%
2017 106.79%
2016 -61.36%
2015 20.01%
2014 26.03%
2013 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$529.40 35.78%
US
$1.01K 52.07%
NL
$111.31 -36.83%
AU
$735.86 6.87%
CH
$257.75 13.01%
BE